Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm tislelizumab consolidation after radiotherapy or sequential chemoradiotherapy in locally advanced NSCLC intolerant to concurrent chemoradiotherapy
ChiCTR2200063476Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival at 6 months. Started Sep 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200063476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063476.